Clusterin as a potential marker in distinguishing cervical neoplasia

Analytical and Quantitative Cytology and Histology

Volumn 33, Issue 4, 2011, Pages 223-228

  Lokamani, Ilambarthi ^a   Looi, Mee Lee ^a   Ali, Siti Aishah Md ^b   Dali, Ahmad Zailani Hatta Mohd ^b   Jamal, Rahman ^a  

^a UNIVERSITI KEBANGSAAN MALAYSIA   (Malaysia)

^b Department of Mechanical Engineering Faculty of Engineering Sungai Besi Camp   (Malaysia)

Author keywords

Cervical cancer; Cervical dysplasia; Clusterin

Indexed keywords

BIOLOGICAL MARKER; CLUSTERIN;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER GRADING; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; DIAGNOSTIC VALUE; DISEASE COURSE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SQUAMOUS CELL CARCINOMA; SQUAMOUS EPITHELIUM; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CELL DIFFERENTIATION; CLUSTERIN; EPITHELIUM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 80955141033     PISSN: 08846812     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Lim CC, Yahaya H: Second Report of the National Cancer Registry Cancer Incidence in Malaysia. National Cancer Registry, 2004
2. Yan S: Diagnostic role of immunohistochemistry in prostate cancer. IV(1): [Cited 6 January 2011]. Available at: http://petersonlab.pdswebpro.com/UserFiles/File/SPL%20winter%202010.pdf
3. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792
4. Looi ML, Karsani SA, Rahman MA, Dali AZ, Ali SA, Ngah WZ, Yusof YA: Plasma proteome analysis of cervical intraepithelial neoplasia and cervical squamous cell carcinoma. J Biosci 2009;34:917-925
5. Pucci S, Bonanno E, Pichiorri F, Angeloni C, Spagnoli LG: Modulation of different clusterin isoforms in human colon tumorigenesis. Oncogene 2004;23:2298-2304
6. Redondo M, Villar E, Torres-Muñoz J, Tellez T, Morell M, Petito CK: Overexpression of clusterin in human breast carcinoma. Am J Pathol 2000;157:393-399
7. Kevans D, Foley J, Tenniswood M, Sheahan K, Hyland J, O'Donoghue D, Mulcahy H, O'Sullivan J: High clusterin expression correlates with a poor outcome in stage II colorectal cancers. Cancer Epidemiol Biomarkers Prev 2009;18:393-399
8. Shannan B, Seifert M, Leskov K, Willis J, Boothman D, Tilgen W, Reichrath J: Challenge and promise: Roles for clusterin in pathogenesis, progression and therapy of cancer. Cell Death Differ 2006;13:12-19
9. Thomas-Tikhonenko A, Viard-Leveugle I, Dews M, Wehrli P, Sevignani C, Yu D, Ricci S, el-Deiry W, Aronow B, Kaya G, Saurat JH, French LE: Myc-transformed epithelial cells down-regulate clusterin, which inhibits their growth in vitro and carcinogenesis in vivo. Cancer Res 2004;64:3126-3136
10. Park DC, Yeo SG, Shin EY, Mok SC, Kim DH: Clusterin confers paclitaxel resistance in cervical cancer. Gynecol Oncol 2006;103:996-1000
11. Watari H, Ohta Y, Hassan MK, Xiong Y, Tanaka S, Sakuragi N: Clusterin expression predicts survival of invasive cervical cancer patients treated with radical hysterectomy and systematic lymphadenectomy. Gynecol Oncol 2008;108:527-532
12. Kurahashi T, Muramaki M, Yamanaka K, Hara I, Miyake H: Expression of the secreted form of clusterin protein in renal cell carcinoma as a predictor of disease extension. BJU Int 2005;96:895-899
13. Yang GF, Li XM, Xie D: Overexpression of clusterin in ovarian cancer is correlated with impaired survival. Int J Gynecol Cancer 2009;19:1342-1346
14. Xie MJ, Motoo Y, Su SB, Mouri H, Ohtsubo K, Matsubara F, Sawabu N: Expression of clusterin in human pancreatic cancer. Pancreas 2002;25:234-238
15. Miyake H, Muramaki M, Kurahashi T, Yamanaka K, Hara I, Gleave M, Fujisawa M: Expression of clusterin in prostate cancer correlates with Gleason score but not with prognosis in patients undergoing radical prostatectomy without neoadjuvant hormonal therapy. Urology 2006;68:609-614
16. Zhou LQ, Yang XZ, Zeng L, Liang LL, Yang XY, Ren L, Chung L, Zhang ZW, Na YQ, Gu FL, Guo YL: Expression and significance of clusterin in normal prostate, benign prostate hyperplasia and prostate cancer. Zhonghua Wai Ke Za Zhi 2003;41:93-95
17. Pins MR, Fiadjoe JE, Korley F, Wong M, Rademaker AW, Jovanovic B, Yoo TK, Kozlowski JM, Raji A, Yang XJ, Lee C: Clusterin as a possible predictor for biochemical recurrence of prostate cancer following radical prostatectomy with intermediate Gleason scores: A preliminary report. Prostate Cancer Prostatic Dis 2004;7:243-248
18. Xie D, Sham JS, Zeng WF, Che LH, Zhang M, Wu HX, Lin HL, Wen JM, Lau SH, Hu L, Guan XY: Oncogenic role of clusterin overexpression in multistage colorectal tumorigenesis and progression. World J Gastroenterol 2005;11:3285-3289
19. Shrestha E: The expression and clinical significance of clusterin and ki67 in cervical cancer. In the Proceedings of the 2009 American Society of Clinical Oncology Annual Meeting (Post-Meeting Edition). J Clin Oncol (Suppl) 2009;27:e16554
20. Kalof AN, Cooper K: Our approach to squamous intraepithelial lesions of the uterine cervix. J Clin Pathol 2007;60: 449-455